Non-canonical dihydrolipoyl transacetylase promotes chemotherapy resistance via mitochondrial tetrahydrofolate signaling

Jung Seok Hwang, JiHoon Kang, Jaehyun Kim, Kiyoung Eun, Sophia West, Hannah E. Bacho, Vanessa Avalos, Sydney Shuff, Dong M. Shin, Nabil F. Saba, Kelly R. Magliocca, Cheng-Kui Qu, Haian Fu, Suresh S. Ramalingam, Andrey A. Ivanov, Taro Hitosugi and Sumin Kang ()
Additional contact information
Jung Seok Hwang: Emory University School of Medicine
JiHoon Kang: Emory University School of Medicine
Jaehyun Kim: Emory University School of Medicine
Kiyoung Eun: Emory University School of Medicine
Sophia West: Emory University School of Medicine
Hannah E. Bacho: Emory University School of Medicine
Vanessa Avalos: Emory University School of Medicine
Sydney Shuff: Emory University School of Medicine
Dong M. Shin: Emory University School of Medicine
Nabil F. Saba: Emory University School of Medicine
Kelly R. Magliocca: Emory University School of Medicine
Cheng-Kui Qu: Emory University School of Medicine
Haian Fu: Emory University School of Medicine
Suresh S. Ramalingam: Emory University School of Medicine
Andrey A. Ivanov: Emory University School of Medicine
Taro Hitosugi: Mayo Clinic
Sumin Kang: Emory University School of Medicine

Nature Communications, 2025, vol. 16, issue 1, 1-18

Abstract: Abstract Chemotherapy is often a primary treatment for cancer. However, resistance leads to therapeutic failure. Acetylation dynamics play important regulatory roles in cancer cells, but the mechanisms by which acetylation mediates therapy resistance remain poorly understood. Here, using acetylome-focused RNA interference (RNAi) screening, we find that acetylation induced by mitochondrial dihydrolipoyl transacetylase (DLAT), independent of the pyruvate dehydrogenase complex, is pivotal in promoting resistance to chemotherapeutics, such as cisplatin. Mechanistically, DLAT acetylates methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) at lysine 44 and promotes 10-formyl-tetrahydrofolate (10-formyl-THF) and consequent mitochondrially encoded cytochrome c oxidase II (MT-CO2) induction. DLAT signaling is elevated in cancer patients refractory to chemotherapy or chemoimmunotherapy. A decoy peptide DMp39, designed to target DLAT signaling, effectively sensitizes cancer cells to cisplatin in patient-derived xenograft models. Collectively, our study reveals the crucial role of DLAT in shaping chemotherapy resistance, which involves an interplay between acetylation signaling and metabolic reprogramming, and offers a unique decoy peptide technology to overcome chemotherapy resistance.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-63892-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-63892-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-63892-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().